Top Page
SSY Group
(2005)
SSY Group (2005) vs. iShares MSCI Hong Kong ETF (EWH)
SSY Group Business Overview & Revenue Model
SSY Group Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.58B | 5.77B | 6.46B | 6.43B | 5.36B | 4.26B |
| Gross Profit | 1.96B | 2.91B | 3.62B | 3.44B | 3.04B | 2.58B |
| EBITDA | 1.25B | 1.74B | 2.11B | 1.86B | 1.40B | 1.09B |
| Net Income | 658.92M | 1.06B | 1.32B | 1.12B | 785.53M | 611.97M |
Balance Sheet | ||||||
| Total Assets | 12.79B | 12.60B | 11.97B | 10.97B | 10.71B | 9.25B |
| Cash, Cash Equivalents and Short-Term Investments | 1.52B | 1.29B | 1.62B | 1.71B | 1.70B | 1.51B |
| Total Debt | 4.02B | 3.64B | 3.37B | 3.21B | 3.11B | 2.44B |
| Total Liabilities | 5.19B | 5.07B | 4.70B | 4.42B | 4.22B | 3.34B |
| Stockholders Equity | 7.27B | 7.22B | 6.93B | 6.21B | 6.22B | 5.65B |
Cash Flow | ||||||
| Free Cash Flow | 94.40M | -49.39M | 221.88M | 368.70M | 359.58M | 236.61M |
| Operating Cash Flow | 381.69M | 491.03M | 925.75M | 786.82M | 747.91M | 527.64M |
| Investing Cash Flow | -354.67M | -521.76M | -640.19M | -402.72M | -681.23M | -287.58M |
| Financing Cash Flow | -234.64M | -295.42M | -304.57M | -190.51M | 136.13M | 366.35M |
SSY Group Technical Analysis
SSY Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $9.09B | 13.81 | 9.12% | 4.68% | -29.18% | -51.49% | |
| ― | HK$6.47B | 7.25 | 10.85% | 5.89% | -20.64% | -25.39% | |
| ― | HK$12.49B | 11.68 | 25.92% | 4.19% | 19.05% | 13.68% | |
| ― | HK$1.79B | 9.39 | 5.34% | 5.25% | 2.89% | -68.83% | |
| ― | HK$10.01B | 10.82 | 7.48% | 4.31% | 1.65% | -16.38% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $13.62B | ― | -1.87% | 0.73% | 19.21% | -115.91% |
SSY Group Corporate Events
SSY Group Limited has announced the approval of Levamlodipine Besilate Tablets by the National Medical Products Administration of China. This development signifies a strategic advancement in their product offerings, potentially enhancing their market position in the pharmaceutical industry by addressing key health conditions like hypertension and angina.
The most recent analyst rating on (HK:2005) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that its Ambroxol Hydrochloride has received approval from China’s National Medical Products Administration to be marketed as a bulk drug. This development signifies a significant advancement in the company’s product offerings, potentially enhancing its market position in the respiratory treatment sector.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced the approval for drug production and registration of two new chemical drug products by the National Medical Products Administration of China. The newly approved products, Calcium Gluconate and Sodium Chloride Injection and Morinidazole and Sodium Chloride Injection, are expected to enhance the company’s product portfolio, addressing conditions such as acute hypocalcemia and gynecological pelvic inflammatory diseases. This development signifies a strategic advancement in SSY Group’s market positioning, potentially strengthening its competitive edge in the pharmaceutical industry.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that its Indocyanine Green product has received approval from China’s National Medical Products Administration for registration as a bulk drug. This development allows the product to be used for diagnosing liver diseases and choroidal angiography, potentially enhancing the company’s market presence and offering new diagnostic solutions.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of seven new drugs. These drugs include treatments for hypertension, heart failure, reproductive health, and other medical conditions, marking a significant advancement in the company’s product offerings and potentially strengthening its position in the Chinese pharmaceutical market.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Allopurinol Tablets, a type 3 chemical drug. This development marks a significant step in the company’s product portfolio, enhancing its market position in the pharmaceutical industry by offering treatments for gout and other related conditions. The approval is expected to positively impact the company’s operations and provide new opportunities for growth and stakeholder engagement.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that it received approvals from the National Medical Products Administration of China for the production and registration of three new drugs: Urapidil Sustained-release Capsules, Nicardipine Hydrochloride and Sodium Chloride Injection, and Drotaverine Hydrochloride Injection. These approvals mark significant milestones as they are the first of such approvals for these types of drugs in China, potentially enhancing SSY Group’s market position and expanding its product offerings in the pharmaceutical industry.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited reported a challenging first half of 2025, with a significant decline in revenue and net profit due to a complex external environment and declining product prices. Despite these challenges, the company remains committed to its innovation-driven strategy, optimizing its product mix, and expanding market share. The company achieved notable success in centralized procurement projects, enhancing its regional market influence and facilitating market access for new products.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced an interim cash dividend of HKD 0.05 per share for the six months ending June 30, 2025. This dividend reflects the company’s ongoing commitment to providing returns to its shareholders and may enhance its attractiveness to investors. The ex-dividend date is set for September 11, 2025, with payment scheduled for September 26, 2025.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of its Benidipine Hydrochloride Tablets, used for treating primary hypertension and angina pectoris. This development marks a significant step in the company’s product offerings, potentially enhancing its market position and providing stakeholders with new opportunities in the pharmaceutical sector.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that its antibiotic, Morinidazole, has received registration approval from China’s National Medical Products Administration. This development allows the drug to be marketed as a bulk drug for treating appendicitis and pelvic inflammatory disease caused by anaerobic bacteria, potentially enhancing the company’s market position and offering new opportunities for growth.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that its Board of Directors will convene on August 28, 2025, to approve the unaudited interim results for the first half of 2025 and discuss the potential payment of an interim dividend. This meeting is significant as it will provide insights into the company’s financial health and strategic direction, impacting stakeholders’ expectations and the company’s market positioning.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that its drug Azilsartan has received approval from the National Medical Products Administration of China for registration as a bulk drug. This development marks a significant step in the company’s product offerings, potentially enhancing its market position in the hypertension treatment sector.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that its product, Fampridine, has received approval from the National Medical Products Administration of China to be marketed as a bulk drug. This approval marks a significant milestone as it is the first of its kind for PRC entities, potentially enhancing the company’s position in the pharmaceutical market and offering new treatment options for adults with multiple sclerosis.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has announced that its Drotaverine Hydrochloride, an antispasmodic drug used for treating spasms in the biliary, urinary, and gastrointestinal tracts, has received approval for registration from the National Medical Products Administration of China. This development marks a significant step for the company in expanding its product offerings and strengthening its position in the pharmaceutical market, potentially benefiting shareholders and investors.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of Rosuvastatin Calcium and Ezetimibe Tablets (I), a type 4 chemical drug. This approval marks the third such approval for PRC entities, enhancing the company’s position in the pharmaceutical market by expanding its product offerings for treating hypercholesterolemia and hyperlipidemia, potentially benefiting stakeholders through increased market competitiveness.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.